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Abstract
Statin therapy may prevent an excessive inflammatory response
after cardiopulmonary bypass for cardiac surgery. In a recent issue
of Critical Care, Morgan and colleagues present data from a well-
conducted systematic review and meta-analysis of randomised
controlled trials using inflammatory markers as primary outcome
measure. They find that pre-operative statin therapy, compared
with placebo, may reduce various post-operative markers of
systemic inflammation (IL-6, IL-8, C-reactive protein, tumour
necrosis factor-alpha). Their ability to make definitive conclusions is
limited, however, by the suboptimal methodological quality of the
primary studies. Their review suggests that ICU researchers should
focus on developing valid surrogate markers and use these to
accurately describe the mechanisms and effectiveness of novel
therapies before proceeding to large pragmatic trials using
mortality as primary outcome.
In a recent issue of Critical Care, Morgan and colleagues
present the results of a well-conducted systematic review
and meta-analysis of the effect of statin therapy on inflam-
matory markers after cardiac surgery [1]. Observational
evidence suggests that statin therapy may dampen the
inflammatory response following exposure to a significant
trigger and there is currently much interest in using statins to
treat sepsis [2,3]. In this context cardiopulmonary bypass
(CPB) is appealing methodologically because it allows the
study of preventive interventions [4-6]. Fortunately for patients,
mortality following CPB is low, but the methodological
downside of this success is that very large trials of low risk
patients (or somewhat smaller trials of higher risk patients)
are needed to show a mortality effect.
The randomised controlled trials included by Morgan and
colleagues measured post-operative inflammatory markers in
adults receiving a statin or placebo prior to CPB. They found
that statin therapy may reduce post-CPB inflammation as
measured by IL-6, IL-8, C-reactive protein and tumour
necrosis factor-alpha.
The studies included were generally of suboptimal methodo-
logical quality. For example, six of the eight apparently
randomised studies provide no information on sequence
generation and allocation concealment. Three were unblinded
and only two had a low risk of bias (defined by applying the
Cochrane risk of bias tool). The median sample size was 43.5
(range 20 to 200) and the confidence intervals around the
mean differences in inflammatory markers for individual
studies and for the summary estimates were fairly wide. Other
studies of inflammatory biomarkers are likely to vary widely
between patients and within patients over time, suggesting
that analysis of within-patient changes over time may detect
differences between treatment groups with more statistical
power.
While the meta-analysis does not provide a definitive answer,
it raises key methodological issues relevant to sepsis
research in general, and to statin research in critical illness in
particular.
Failure of sepsis studies
The sepsis literature is littered with failed trials of pharmaco-
logical interventions [7,8]. In many instances an initial study
demonstrating benefit was contradicted by subsequent work
[9]. The methodological quality of many of these studies is
variable and frequently the mechanisms (at both biological
and functional levels) through which benefit are supposed to
accrue were not robustly described [10]. We agree with
other authors [8] that the logical sequence of questions to
answer before performing pragmatic mortality trials should
be: first, can statins theoretically beneficially modulate the
immune response in these patient populations? Is it biologi-
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cally plausible? Second, do statins beneficially (and safely)
modulate the immune response and associated physiology?
Third, does the modulated immune response translate into
benefit at the level of organ function?
In this regard the critical care research community can learn
much from colleagues in rheumatology, cardiology and onco-
logy, who have explored and described mechanistic path-
ways - paths reliably connecting biological plausibility and
effect with organ performance and then outcomes important
to patients (for example, mortality) [11]; and developed
reliable and validated surrogate endpoints [11].
Morgan and colleagues want to establish whether potential
surrogate endpoints (inflammatory markers) are modulated,
but herein lay the problems. First, no validated surrogate
endpoints exist for use in critical illness. Second, while data
from successful ‘mortality’ randomised controlled trials may
improve our understanding of surrogate outcomes, inter-
ventions that improve surrogate markers do not necessarily
translate into improved mortality [12-14]. Third, what is the
minimum clinically important difference for a biomarker or
combination of biomarkers? How much should individual (and
aggregate) marker levels differ between groups to translate
into clinical benefit? Lastly, what if ‘good’ markers are also
suppressed and, indeed, how much inflammation is good for
you?
We suggest these issues are important for the following
reasons. It is clear that in this relatively new study area the
knowledge space is already occupied by poor studies and
potentially unreliable data. We would like to encourage
investigators to design studies that are methodologically
robust and provide reliable mechanistic data. ICU
researchers should work towards developing valid surrogate
endpoints to allow robust and reliable translational research,
although we acknowledge that previous success at improving
organ performance has not always improved outcomes
[12-14]. Once validated, these surrogate endpoints should
be used to establish the biological effectiveness of new treat-
ments (and probably some existing ones) before moving on to
pragmatic studies using mortality as outcome measure [15].
Without demonstrating first biological and then functional (for
example, organ performance) effectiveness, we run the risk of
wrongly adding statins to the wasteland of ICU pharmaco-
therapy. On the positive side, the pleiotropic effects of statins
and extensive experience with these agents in cardiology
mean that we may be less likely to fall into a trap constructed
of an insufficient understating of mechanisms combined with
a single-target therapy [2].
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